ONE-SHOT Trial - Ultra-hypofractionated Single-dose SBRT for Prostate Cancer

Critères d'exclusion

• Tumor clinical stage cT3a-3b or T4 • Evidence of T3a, T3b or T4 disease as assessed by MRI • Positive lymph-nodes or metastatic disease from prostate cancer on imaging studies. • Significant tumor on the transitional zone as assessed by MRI • Gleason at biopsy ≥ 4+3 • Androgen deprivation therapy or products known to affect PSA levels • Impossibility to implant Calypso beacons • History of hematologic or primary solid tumor malignancy, unless in remission for at least 3 years from registration with the exception of curatively treated localized non-melanoma skin cancer • Prior pelvic radiotherapy • Previous surgery for prostate cancer • Previous transurethral resection of the prostate (TURP) (\< 12 weeks before registration) • Hip prosthesis • Severe or active co-morbidity likely to impact on the advisability of SBRT • Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications